• +1-646-491-9876
    • +91-20-67278686

    Search

    Insulin Like Growth Factor II-Pipeline Review H2 2017

    Insulin Like Growth Factor II-Pipeline Review H2 2017

    • Report Code ID: RW00011022698
    • Category Life Sciences
    • No. of Pages 50
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Pipeline Review, H2 2017

    Summary

    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Insulin-like growth factor 2 (IGF-2) is a protein hormone. IGF-2 is influenced by placental lactogen and plays a role in fetal development. It undergoes glucose-mediated co-secretion with insulin and acts as physiological amplifier of glucose-mediated insulin secretion. It exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.

    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 9 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Musculoskeletal Disorders which include indications Metastatic Breast Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Hormone Sensitive Breast Cancer, Huntington Disease, Ischemic Cerebral Stroke, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscular Dystrophy, Neuroblastoma, Non-Small Cell Lung Cancer, Parkinson's Disease and Solid Tumor.

    The latest report Insulin Like Growth Factor II-Pipeline Review, H2 2017, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
    -The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Overview 6
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Therapeutics Development 7
    Products under Development by Stage of Development 7
    Products under Development by Therapy Area 8
    Products under Development by Indication 9
    Products under Development by Companies 10
    Products under Development by Universities/Institutes 12
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Therapeutics Assessment 14
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 16
    Assessment by Molecule Type 18
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Companies Involved in Therapeutics Development 20
    Boehringer Ingelheim GmbH 20
    Genervon Biopharmaceuticals LLC 20
    MedImmune LLC 21
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Drug Profiles 22
    dusigitumab-Drug Profile 22
    Product Description 22
    Mechanism Of Action 22
    R&D Progress 22
    GM-6-Drug Profile 23
    Product Description 23
    Mechanism Of Action 23
    R&D Progress 23
    M-610.27-Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    M-630-Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    M-7085-Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer-Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Recombinant Proteins to Inhibit IGF-2 for Oncology-Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    Small Molecules to Inhibit IGF-2 for Oncology-Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    xentuzumab-Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Dormant Products 36
    Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)-Product Development Milestones 37
    Featured News & Press Releases 37
    Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 37
    Jan 10, 2017: Genervon Releases ALS, PD and AD DiseaseĀ­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm 37
    Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways 38
    Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS 39
    May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 39
    May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe 40
    Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression 41
    Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease 41
    Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA 42
    Jan 08, 2015: Genervon Announces ALS Compassionate Use Results 43
    Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results 44
    Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS 46
    Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS 46
    Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604 47
    Jun 26, 2013: Genervon's GM604 Receives Fast Track Designation From FDA For Treatment Of Amyotrophic Lateral Sclerosis 47
    Appendix 49
    Methodology 49
    Coverage 49
    Secondary Research 49
    Primary Research 49
    Expert Panel Validation 49
    Contact Us 49
    Disclaimer 50

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Indication, H2 2017 9
    Number of Products under Development by Companies, H2 2017 10
    Products under Development by Companies, H2 2017 11
    Number of Products under Investigation by Universities/Institutes, H2 2017 12
    Products under Investigation by Universities/Institutes, H2 2017 13
    Number of Products by Stage and Mechanism of Actions, H2 2017 15
    Number of Products by Stage and Route of Administration, H2 2017 17
    Number of Products by Stage and Molecule Type, H2 2017 19
    Pipeline by Boehringer Ingelheim GmbH, H2 2017 20
    Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 20
    Pipeline by MedImmune LLC, H2 2017 21
    Dormant Projects, H2 2017 36

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Top 10 Indications, H2 2017 9
    Number of Products by Mechanism of Actions, H2 2017 14
    Number of Products by Stage and Mechanism of Actions, H2 2017 14
    Number of Products by Routes of Administration, H2 2017 16
    Number of Products by Stage and Routes of Administration, H2 2017 16
    Number of Products by Molecule Types, H2 2017 18
    Number of Products by Stage and Molecule Types, H2 2017 18
    Boehringer Ingelheim GmbH
    Genervon Biopharmaceuticals LLC
    MedImmune LLC

    Request for Sample

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//insulin-like-growth-factor-ii-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments